Clinical Manufacturing Site Approved for Molecular Profiles
Molecular Profiles has opened a new clinical manufacturing facility following a successful inspection from the Medicines and Healthcare products Regulatory Agency.
UK-based contract research and manufacturing organization Molecular Profiles has opened its new facility following a successful inspection from the Medicines and Healthcare products Regulatory Agency (MHRA). The Nottingham-based, pharmaceutical production site will provide clinical manufacturing capabilities.
This new facility marks a significant expansion for the company that started life as a spin-out from Nottingham University more than 15 years ago, the company reports. The investment adds six GMP suites, new laboratories, and a clinical packing area to support clients’ Phase I and II clinical trial projects.
The approval of the company’s cGMP-compliant facility follows a recent visit from Nick Clegg, Deputy Prime Minister of the UK Government, which provided £1.6m to the expansion through the regional growth fund grant. The new manufacturing site supports Molecular Profiles’ alliance with Onyx Scientific, which delivers pharmaceutical development services from drug discovery through the later phases of clinical development.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
